122 related articles for article (PubMed ID: 36958125)
21. Serine Protease Inhibitor Kazal Type 1, A Potential Biomarker for the Early Detection, Targeting, and Prediction of Response to Immune Checkpoint Blockade Therapies in Hepatocellular Carcinoma.
Jia J; Ga L; Liu Y; Yang Z; Wang Y; Guo X; Ma R; Liu R; Li T; Tang Z; Wang J
Front Immunol; 2022; 13():923031. PubMed ID: 35924241
[TBL] [Abstract][Full Text] [Related]
22. Serum cell division cycle 42 in advanced hepatocellular carcinoma patients: Linkage with clinical characteristics and immune checkpoint inhibitor-related treatment outcomes.
Xu J; Shao R; Zhang X; Yao D; Han S
Clin Res Hepatol Gastroenterol; 2023 Aug; 47(7):102149. PubMed ID: 37247692
[TBL] [Abstract][Full Text] [Related]
23. Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody.
Liu G; Zhou W; Li X; Guo L; He T; Zhao J; Gong L
Front Immunol; 2021; 12():712351. PubMed ID: 34504494
[TBL] [Abstract][Full Text] [Related]
24. Non-measurable infiltrative HCC: is post-contrast attenuation on CT a sign of tumor response?
Koulakian H; Allaham W; Vilgrain V; Ronot M
Eur Radiol; 2019 Aug; 29(8):4389-4399. PubMed ID: 30413965
[TBL] [Abstract][Full Text] [Related]
25. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma.
Cheng AL; Hsu C; Chan SL; Choo SP; Kudo M
J Hepatol; 2020 Feb; 72(2):307-319. PubMed ID: 31954494
[TBL] [Abstract][Full Text] [Related]
26. Real-world efficacy and safety of immune checkpoint inhibitors in advanced hepatocellular carcinoma: Experience of a tertiary Asian Center.
Ng KYY; Wong LWJ; Ang AJS; Tan SH; Choo SP; Tai DW; Lee JJX
Asia Pac J Clin Oncol; 2021 Oct; 17(5):e249-e261. PubMed ID: 32875742
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic Value of Quantitative Perfusion Computed Tomography Technique in the Assessment of Tumor Response to Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
Ippolito D; Querques G; Pecorelli A; Talei Franzesi C; Okolicsanyi S; Strazzabosco M; Sironi S
J Comput Assist Tomogr; 2019; 43(2):206-213. PubMed ID: 30407241
[TBL] [Abstract][Full Text] [Related]
28. Tumor attenuation and quantitative analysis of perfusion parameters derived from tri-phasic CT scans in hepatocellular carcinoma: Relationship with histological grade.
Pang G; Shao C; Lv Y; Zhao F
Medicine (Baltimore); 2021 Apr; 100(16):e25627. PubMed ID: 33879737
[TBL] [Abstract][Full Text] [Related]
29. Histogram Analysis of CT Perfusion of Hepatocellular Carcinoma for Predicting Response to Transarterial Radioembolization: Value of Tumor Heterogeneity Assessment.
Reiner CS; Gordic S; Puippe G; Morsbach F; Wurnig M; Schaefer N; Veit-Haibach P; Pfammatter T; Alkadhi H
Cardiovasc Intervent Radiol; 2016 Mar; 39(3):400-8. PubMed ID: 26216725
[TBL] [Abstract][Full Text] [Related]
30. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.
Edeline J; Boucher E; Rolland Y; Vauléon E; Pracht M; Perrin C; Le Roux C; Raoul JL
Cancer; 2012 Jan; 118(1):147-56. PubMed ID: 21713764
[TBL] [Abstract][Full Text] [Related]
31. Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma.
Kim CG; Kim C; Yoon SE; Kim KH; Choi SJ; Kang B; Kim HR; Park SH; Shin EC; Kim YY; Kim DJ; Chung HC; Chon HJ; Choi HJ; Lim HY
J Hepatol; 2021 Feb; 74(2):350-359. PubMed ID: 32810553
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic value of dynamic contrast-enhanced CT with perfusion imaging in the quantitative assessment of tumor response to sorafenib in patients with advanced hepatocellular carcinoma: A feasibility study.
Ippolito D; Querques G; Okolicsanyi S; Franzesi CT; Strazzabosco M; Sironi S
Eur J Radiol; 2017 May; 90():34-41. PubMed ID: 28583645
[TBL] [Abstract][Full Text] [Related]
33. Case Report: Antiangiogenic Therapy Plus Immune Checkpoint Inhibitors Combined With Intratumoral Cryoablation for Hepatocellular Carcinoma.
Li X; Xu J; Gu X; Chen L; Wu Q; Li H; Bai H; Yang J; Qian J
Front Immunol; 2021; 12():740790. PubMed ID: 34733279
[TBL] [Abstract][Full Text] [Related]
34. Parametric response mapping cut-off values that predict survival of hepatocellular carcinoma patients after TACE.
Nörthen A; Asendorf T; Shin HO; Hinrichs JB; Werncke T; Vogel A; Kirstein MM; Wacker FK; Rodt T
Abdom Radiol (NY); 2018 Dec; 43(12):3288-3300. PubMed ID: 29680967
[TBL] [Abstract][Full Text] [Related]
35. Using mouse liver cancer models based on somatic genome editing to predict immune checkpoint inhibitor responses.
Yuen VW; Chiu DK; Law CT; Cheu JW; Chan CY; Wong BP; Goh CC; Zhang MS; Xue HD; Tse AP; Zhang Y; Lau HY; Lee D; Au-Yeung RKH; Wong CM; Wong CC
J Hepatol; 2023 Feb; 78(2):376-389. PubMed ID: 36455783
[TBL] [Abstract][Full Text] [Related]
36. Correlation between Dual-Energy and Perfusion CT in Patients with Hepatocellular Carcinoma.
Gordic S; Puippe GD; Krauss B; Klotz E; Desbiolles L; Lesurtel M; Müllhaupt B; Pfammatter T; Alkadhi H
Radiology; 2016 Jul; 280(1):78-87. PubMed ID: 26824712
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of sorafenib for hepatocellular carcinoma by contrast-enhanced ultrasonography: a pilot study.
Shiozawa K; Watanabe M; Kikuchi Y; Kudo T; Maruyama K; Sumino Y
World J Gastroenterol; 2012 Oct; 18(40):5753-8. PubMed ID: 23155317
[TBL] [Abstract][Full Text] [Related]
38. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
Wong JSL; Kwok GGW; Tang V; Li BCW; Leung R; Chiu J; Ma KW; She WH; Tsang J; Lo CM; Cheung TT; Yau T
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563773
[TBL] [Abstract][Full Text] [Related]
39. Hepatocellular carcinoma: the role of helical biphasic contrast-enhanced CT versus CT during arterial portography.
Kanematsu M; Oliver JH; Carr B; Baron RL
Radiology; 1997 Oct; 205(1):75-80. PubMed ID: 9314965
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of efficacy of transcatheter arterial chemoembolization combined with computed tomography-guided radiofrequency ablation for hepatocellular carcinoma using magnetic resonance diffusion weighted imaging and computed tomography perfusion imaging: A prospective study.
Shao GL; Zheng JP; Guo LW; Chen YT; Zeng H; Yao Z
Medicine (Baltimore); 2017 Jan; 96(3):e5518. PubMed ID: 28099329
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
